Group One Trading’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-2,200
| Closed | -$2.79K | – | 8487 |
|
|
2023
Q3 | $2.79K | Buy |
+2,200
| New | +$1.92K | ﹤0.01% | 6933 |
|
|
2023
Q1 | – | Sell |
-1,500
| Closed | -$795 | – | 8189 |
|
|
2022
Q4 | $795 | Sell |
1,500
-300
| -17% | -$190 | ﹤0.01% | 6881 |
|
|
2022
Q3 | $1K | Sell |
1,800
-11,500
| -86% | -$13K | ﹤0.01% | 7413 |
|
|
2022
Q2 | $15K | Sell |
13,300
-16,700
| -56% | -$21.3K | ﹤0.01% | 6535 |
|
|
2022
Q1 | $62K | Sell |
30,000
-24,900
| -45% | -$59.2K | ﹤0.01% | 5944 |
|
|
2021
Q4 | $158K | Sell |
54,900
-6,300
| -10% | -$23.3K | ﹤0.01% | 5319 |
|
|
2021
Q3 | $259K | Sell |
61,200
-34,600
| -36% | -$154K | ﹤0.01% | 4909 |
|
|
2021
Q2 | $507K | Buy |
95,800
+36,600
| +62% | +$176K | ﹤0.01% | 4211 |
|
|
2021
Q1 | $275K | Buy |
59,200
+24,700
| +72% | +$112K | ﹤0.01% | 4682 |
|
|
2020
Q4 | $114K | Sell |
34,500
-15,000
| -30% | -$57K | ﹤0.01% | 4475 |
|
|
2020
Q3 | $164K | Sell |
49,500
-241,400
| -83% | -$887K | ﹤0.01% | 3823 |
|
|
2020
Q2 | $980K | Buy |
290,900
+204,000
| +235% | +$965K | ﹤0.01% | 2036 |
|
|
2020
Q1 | $333K | Sell |
86,900
-22,400
| -20% | -$104K | ﹤0.01% | 2352 |
|
|
2019
Q4 | $660K | Sell |
109,300
-8,300
| -7% | -$56.8K | ﹤0.01% | 2212 |
|
|
2019
Q3 | $889K | Buy |
117,600
+75,500
| +179% | +$851K | 0.01% | 1834 |
|
|
2019
Q2 | $570K | Sell |
42,100
-13,700
| -25% | -$158K | 0.01% | 2023 |
|
|
2019
Q1 | $302K | Buy |
55,800
+14,200
| +34% | +$69.1K | ﹤0.01% | 2380 |
|
|
2018
Q4 | $124K | Sell |
41,600
-5,800
| -12% | -$31.8K | ﹤0.01% | 3044 |
|
|
2018
Q3 | $387K | Sell |
47,400
-54,700
| -54% | -$420K | ﹤0.01% | 2495 |
|
|
2018
Q2 | $994K | Buy |
102,100
+48,600
| +91% | +$498K | 0.01% | 1734 |
|
|
2018
Q1 | $465K | Buy |
53,500
+12,000
| +29% | +$129K | ﹤0.01% | 2120 |
|
|
2017
Q4 | $520K | Buy |
41,500
+1,100
| +3% | +$12.6K | ﹤0.01% | 2225 |
|
|
2017
Q3 | $338K | Sell |
40,400
-33,100
| -45% | -$350K | ﹤0.01% | 2372 |
|
|
2017
Q2 | $1.25M | Sell |
73,500
-2,500
| -3% | -$49.7K | 0.01% | 1285 |
|
|
2017
Q1 | $1.53M | Buy |
76,000
+74,500
| +4,967% | +$1.48M | 0.02% | 1043 |
|
|
2016
Q4 | $23K | Sell |
1,500
-2,000
| -57% | -$26.9K | ﹤0.01% | 3658 |
|
|
2016
Q3 | $46K | Buy |
+3,500
| New | +$33.2K | ﹤0.01% | 3392 |
|
Group One Trading's ZYNE Position: Q3 2023 in Review
Group One Trading sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2023, closing a stake of 4,559 shares — an estimated $3.98K sold.
Group One Trading first reported a position in ZYNE in Q2 2017 and held it in 22 quarters. The position peaked at $1.51M in Q2 2019. 43 funds tracked by Wall St. Rank hold ZYNE as of Q3 2023.
- Group One Trading reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2023 after selling out during the quarter.
- Group One Trading sold 4,559 Zynerba Pharmaceuticals, Inc shares in Q3 2023, an estimated $3.98K.
- Group One Trading first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2017 and held it in 22 quarters.
- Group One Trading's Zynerba Pharmaceuticals, Inc position peaked at $1.51M in Q2 2019.
- 43 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2023.
Based on Group One Trading's 13F filing for Q3 2023, filed 9 Nov 2023.